Summary | Promoter substitution for immunoglobin therapy

This is the pilot version of Therapoid. Register or Sign in as a pilot user to collaborate.

Provided by: Oklahoma Medical Research Foundation (OMRF)
Tags: anti-cancer cancer Breast Cancer GPCR Cell Line

Short Description:

This technology pertains to immunoglobin (Ig) promoters, in particular murine Ig promoters, to function differentially.